Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in obesity pharmacotherapy.

D H Ryan1

  • 1Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA. ryandh@mhs.pbrc.edu

Current Opinion in Gastroenterology
|October 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.

Obesity pillars·2026
Same author

Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET study.

Obesity pillars·2025
Same author

The magnetic structure and spin-reorientation of ErGa.

Acta crystallographica Section B, Structural science, crystal engineering and materials·2024
Same author

Magnetic crystalline-symmetry-protected axion electrodynamics and field-tunable unpinned Dirac cones in EuIn<sub>2</sub>As<sub>2</sub>.

Nature communications·2021
Same author

Efficacy and safety of an oral device to reduce food intake and promote weight loss.

Obesity science & practice·2018
Same author

Magnetic properties of Ln<sub>2</sub>CoGe<sub>4</sub>O<sub>12</sub> and LnBCoGe<sub>4</sub>O<sub>12</sub> (Ln = Gd, Tb, Dy, Ho, Er; B = Sc, Lu).

Dalton transactions (Cambridge, England : 2003)·2017
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

New obesity medications like sibutramine and orlistat offer long-term treatment options. Dexfenfluramine was withdrawn due to heart valve risks, highlighting the importance of safety in obesity pharmacotherapy.

Area of Science:

  • Pharmacology
  • Cardiology
  • Public Health

Background:

  • Rising global obesity rates necessitate effective pharmacotherapy.
  • Recent advancements in understanding energy balance biology inform drug development.
  • A 20-year gap in new obesity drug approvals has been recently addressed.

Purpose of the Study:

  • To review clinical trial data for recently approved obesity medications.
  • To update evidence on the cardiac risks associated with dexfenfluramine.
  • To discuss the role of sibutramine and orlistat in long-term obesity management.

Main Methods:

  • Literature review of recent publications on obesity pharmacotherapy.
  • Analysis of clinical trial experiences with sibutramine and orlistat.

Related Experiment Videos

  • Examination of evidence linking fenfluramine and dexfenfluramine to valvulopathy.

    • Main Results:

    • Dexfenfluramine was withdrawn from the market due to valvular regurgitation risks.
    • Sibutramine (a monoamine reuptake inhibitor) and orlistat (a lipase inhibitor) are approved for long-term use.
    • Ongoing research continues to expand pharmacologic options for obesity.

    Conclusions:

    • Sibutramine and orlistat represent important new options for obesity pharmacotherapy.
    • The withdrawal of dexfenfluramine underscores the critical need for cardiovascular safety monitoring.
    • Continued research is essential to address the growing public health challenge of obesity.